Programa de trasplante de médula ósea - Ensayos clínicos - Mayo Clinic

COVID-19 consejos información actualizada y opciones de vacunas

Infórmate sobre la COVID-19 y las vacunas contra esta enfermedad, y conoce las novedades para pacientes y visitantes de Mayo Clinic. Para navegación del sitio Para acceso a contenido Este contenido no tiene una versión en inglésEste contenido no tiene una versión en árabe Search Pida una consulta Para encontrar un doctor Para encontrar trabajo Para donar Acceso a su cuenta de paciente Español English العربية 简体中文 Twitter Facebook Pinterest YouTube Menú Solicite una Consulta Departamentos y centros Centros y departamentos médicos

Programa de trasplante de médula ósea

Ensayos clínicos

Solicite una Consulta en Mayo Clinic Centros, viajes y alojamientoInvestigación Aug. 27, 2022 Comparte en: FacebookTwitter A continuación, se enumeran los ensayos clínicos actuales.
8 estudios en Programa de trasplante de médula ósea
(solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc.

A Study of Patients Treated for Chronic Granulomatous Disease Since 1995

Rochester, Minn. Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. The purpose of this study is to determine the long term medical condition and daily functioning of patients with CGD after a transplant and if possible, compare these results to patients who do not undergo a transplant.

A Study to Assess Feasibility and Benefit of a Patient-reported Outcomes Quality of Life Tool for Hematology and Medical Oncology

Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the feasibility and benefit of a patient-reported outcomes quality of life tool for hematology and medical oncology.

A Study to Evaluate Cancer Distress Psychological Trauma and Resiliency in Hospitalized Hematopoietic Stem Cell Transplant Patients

Jacksonville, Fla. The purpose of this study is to better understand the distress experience of hospitalized patients undergoing hematopoietic stem cell transplant (HSCT), and to examine the relationship between cancer distress, psychological trauma, and resiliency over time.

A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions

Rochester, Minn. The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors.

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma OPTIMUM Trial

Rochester, Minn. This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.

Hematopoietic Stem Cell Transplant Survivors Study HTSS Study

Rochester, Minn. The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Rochester, Minn., Jacksonville, Fla. This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.

A Study to Assess Older Adults Applying Pre-transplant Comorbidity Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant CHARM

Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of one year NRM.

Mayo Clinic de Rochester Minnesota y Mayo Clinic de Phoenix y Scottsdale Arizona han sido reconocidas entre los mejores hospitales oncoló gicos del paí s durante el perí odo 2022-2023 por U S News and World Report

Lee más sobre este gran honor.

Programa de trasplante de médula ósea

Página inicial del departamentoSeccionesSolicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por sede y especialidadConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicElegibilidadVolúmenes y resultadosRemisionesComunícate con nosotros

Investigación todo es por los pacientes

Secciones

Solicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por sede y especialidadConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicElegibilidadVolúmenes y resultadosRemisiones ORG-20193492 Departamentos y centros Centros y departamentos médicos Programa de trasplante de médula ósea